A nootropic drug with a pronounced antiamnestic effect, promotes memory consolidation, facilitates the learning process, increases the resistance of brain tissue to toxic effects, and has an anticonvulsant effect.
It has a positive effect on metabolic processes, stimulates redox processes, increases the energy potential of the body through the use of glucose. It increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABA and GABA receptors, and does not significantly affect the spontaneous bioelectrical activity of the brain.
It has no effect on respiration and the cardiovascular system, exhibits an unexpressed diuretic effect, and has anorectic activity when used as a course.
The stimulating effect is manifested in the ability to provide a moderately pronounced effect, manifested in relation to motor reactions, increasing physical performance, as well as weakening the severity of the hypnotic effect of ethanol and hexobarbital.
The psychostimulatory effect predominates in the ideational sphere.
The adaptogenic effect is manifested in an increase in the body's resistance to stress in conditions of excessive mental and physical exertion, with fatigue, hypokinesia and immobilization, at low temperatures.
Against the background of taking the drug, an improvement in vision was observed, which is manifested in an increase in visual acuity, brightness and fields.
Improves blood flow to the lower extremities.
It stimulates the production of antibodies in response to the administration of antigens, which indicates immunostimulating properties, but at the same time does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.
With the use of the course, drug dependence, tolerance, 'withdrawal syndrome' do not develop.
The effect manifests itself in a single dose, which is important when using the drug in extreme conditions.
Indications for use
- Diseases of the central nervous system of various origins, accompanied by a deterioration of intellectual and memory functions, a decrease in motor activity.
- Neurotic affections, manifested by impaired memory.
- Violations of the learning process.
- Psycho-organic syndromes, manifested by intellectual-mnstic disorders.
- convulsive states.
- Obesity (food-constitutional genesis).
- Prevention of hypoxia, increased resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and increase mental and physical performance.
- Chronic alcoholism (in order to reduce intellectual and memory disorders).
Phenylpiracetam can enhance the effect of drugs that stimulate the central nervous system, and nootropic drugs.
Phenylpiracetam exhibits pronounced antagonism to the catalytic effect of neuroleptics, and also weakens the severity of the hypnotic effect of ethanol and hexobarbital.
Take immediately after meals. Your doctor should determine the dose and duration of treatment. Doses vary depending on the patient's condition. The average single dose is 150 mg (100 to 250 mg), the average daily dose is 250 mg (200 to 300 mg). The maximum daily dose of Nanotropil novo is 750 mg. It is recommended to take a daily dose of up to 100 mg once in the morning, and more than 100 mg should be divided into 2 doses. The duration of treatment can vary from 2 weeks to 3 months, with an average of 30 days. If necessary, the course can be repeated after 1 month.
To increase efficiency – 100-200 mg once in the morning, for 2 weeks (for athletes – 3 days).
The recommended duration of drug therapy in patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning). It is not recommended to take the drug later than 15 hours.